Curtis et al., 2012 - Google Patents
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityCurtis et al., 2012
View HTML- Document ID
- 3845248416057029143
- Author
- Curtis J
- van der Helm‐van Mil A
- Knevel R
- Huizinga T
- Haney D
- Shen Y
- Ramanujan S
- Cavet G
- Centola M
- Hesterberg L
- Chernoff D
- Ford K
- Shadick N
- Hamburger M
- Fleischmann R
- Keystone E
- Weinblatt M
- Publication year
- Publication venue
- Arthritis care & research
External Links
Snippet
Objective Quantitative assessment of disease activity in rheumatoid arthritis (RA) is important for patient management, and additional objective information may aid rheumatologists in clinical decision making. We validated a recently developed …
- 230000000694 effects 0 title abstract description 97
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Curtis et al. | Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity | |
Centola et al. | Development of a multi-biomarker disease activity test for rheumatoid arthritis | |
Mjaavatten et al. | Early rheumatoid arthritis: the performance of the 2010 ACR/EULAR criteria for diagnosing RA | |
Liao et al. | Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis | |
Wang et al. | Progression of nonradiographic axial spondyloarthritis to ankylosing spondylitis: a population‐based cohort study | |
Visser | Early diagnosis of rheumatoid arthritis | |
Abildtrup et al. | Calprotectin as a biomarker for rheumatoid arthritis: a systematic review | |
Lukas et al. | Favorable effect of very early disease‐modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Étude et Suivi des Polyarthrites Indifférenciées Récentes (Study and Followup of Early Undifferentiated Polyarthritis) | |
Van der Linden et al. | Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria | |
van der Helm-van Mil et al. | An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression | |
JP5675829B2 (en) | Biomarkers and methods for measuring and monitoring inflammatory disease activity | |
Suter et al. | Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis | |
Van der Linden et al. | Toward a data‐driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: Is it sensible to look at levels of rheumatoid factor? | |
Young et al. | Relatives without rheumatoid arthritis show reactivity to anti–citrullinated protein/peptide antibodies that are associated with arthritis‐related traits: studies of the etiology of rheumatoid arthritis | |
Meeuwisse et al. | Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint | |
Jawaheer et al. | Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients | |
Johnson et al. | Correlation of the Multi‐Biomarker disease activity score with rheumatoid arthritis disease activity measures: a systematic review and Meta‐Analysis | |
Doss et al. | Phenome‐wide association study of rheumatoid arthritis subgroups identifies association between seronegative disease and fibromyalgia | |
JP7470268B2 (en) | Biomarkers and methods for assessing risk of myocardial infarction and serious infections in patients with rheumatoid arthritis - Patents.com | |
Roodenrijs et al. | Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis | |
JP2025013479A (en) | Biomarkers and methods for assessing disease activity in psoriatic arthritis - Patents.com | |
Boeters et al. | ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation | |
Alemao et al. | Association of seropositivity and mortality in rheumatoid arthritis and the impact of treatment with disease‐modifying antirheumatic drugs: results from a real‐world study | |
Kuller et al. | Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis | |
Cornec et al. | Comparison of ACR 1987 and ACR/EULAR 2010 criteria for predicting a 10-year diagnosis of rheumatoid arthritis |